AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding

AstraZeneca established its vaccines unit after collaborating with the University of Oxford to develop a COVID-19 vaccine. The existing site, currently used for producing the nasal flu vaccine FluMist, is set to be upgraded under the new investment.